Molecular Formula | C14H11NO2S |
Molar Mass | 257.31 |
Storage Condition | 2-8°C |
In vitro study | YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells. YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells. Cell Proliferation Assay Cell Line: MCF-7 and MDA-MB-231 cells Concentration: 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 96 hours Result: Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC 50 =85.8 nM and 4.02 μM, respectively). |
In vivo study | YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo. Animal Model: BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells Dosage: 15 mg/kg Administration: S.c. every 2 days for 63 days Result: Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.886 ml | 19.432 ml | 38.864 ml |
5 mM | 0.777 ml | 3.886 ml | 7.773 ml |
10 mM | 0.389 ml | 1.943 ml | 3.886 ml |
5 mM | 0.078 ml | 0.389 ml | 0.777 ml |
biological activity | YL-109 is a new anti-tumor reagent, which can inhibit the growth and invasion of breast cancer cells in vitro and in vivo. |
in vitro study | YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells. YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells. Cell Proliferation Assay Cell Line: MCF-7 and MDA-MB-231 cells Concentration: 0.001, 0.01, 0.1, 1, 10 μ m Incubation Time: 96 hours Result: Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC 50=85.8 nM and 4.02 μ m, respectively). |
Cell Line: | MCF-7 and MDA-MB-231 cells |
Concentration: | 0.001, 0.01, 0.1, 1, 10 μM |
Incubation Time: | 96 hours |
Result: | Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC 50 =85.8 nM and 4.02 μM, respectively). Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. |
in vivo study | YL-109 (15 mg/kg; S.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo. Animal model: BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells Dosage: 15 mg/kg Administration: S.c. every 2 days for 63 days result: Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. |
Animal Model: | BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells |
Dosage: | 15 mg/kg |
Administration: | S.c. every 2 days for 63 days |